Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum,Cell

当前位置： X-MOL 学术 › Cell › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Cell ( IF 45.5 ) Pub Date : 2022-06-09 , DOI: 10.1016/j.cell.2022.06.005
Aekkachai Tuekprakhon ₁ , Rungtiwa Nutalai ₁ , Aiste Dijokaite-Guraliuc ₁ , Daming Zhou ₂ , Helen M Ginn ₃ , Muneeswaran Selvaraj ₁ , Chang Liu ₄ , Alexander J Mentzer ₅ , Piyada Supasa ₁ , Helen M E Duyvesteyn ₆ , Raksha Das ₁ , Donal Skelly ₇ , Thomas G Ritter ₈ , Ali Amini ₉ , Sagida Bibi ₁₀ , Sandra Adele ₈ , Sile Ann Johnson ₈ , Bede Constantinides ₁₁ , Hermione Webster ₁₁ , Nigel Temperton ₁₂ , Paul Klenerman ₁₃ , Eleanor Barnes ₁₃ , Susanna J Dunachie ₁₄ , Derrick Crook ₁₁ , Andrew J Pollard ₁₅ , Teresa Lambe ₁₆ , Philip Goulder ₁₇ , Neil G Paterson ₃ , Mark A Williams ₃ , David R Hall ₃ , , , Elizabeth E Fry ₆ , Jiandong Huo ₆ , Juthathip Mongkolsapaya ₄ , Jingshan Ren ₆ , David I Stuart ₁₈ , Gavin R Screaton ₄

Affiliation

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich Chatham Maritime, Kent, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Department of Medicine, University of Oxford, Oxford, UK.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Peter Medawar Building for Pathogen Research, Oxford, UK; Department of Paediatrics, University of Oxford, Oxford, UK.
Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa’s Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.

中文翻译：

SARS-CoV-2 Omicron BA.4 和 BA.5 的抗体从疫苗和 BA.1 血清中逃逸

SARS-CoV-2 的 Omicron 谱系于 2021 年 11 月首次被描述，迅速传播并在全球占据主导地位，并已分裂成多个亚谱系。 BA.1 在最初的浪潮中占据主导地位，但在许多国家已被 BA.2 取代。最近来自南非豪登省地区的测序发现了两个新的亚系 BA.4 和 BA.5，它们正在当地占据主导地位，推动了新的浪潮。 BA.4 和 BA.5 包含相同的刺突序列，虽然与 BA.2 密切相关，但它们的刺突受体结合域中包含进一步的突变。在这里，我们使用一系列疫苗和天然免疫血清以及单克隆抗体组研究 BA.4/5 的中和作用。与BA.1和BA.2相比，BA.4/5显示来自接种三倍剂量的阿斯利康或辉瑞疫苗的个体的血清的中和作用降低。此外，使用来自 BA.1 疫苗突破性感染的血清，同样会显着降低 BA.4/5 的中和作用，从而增加了重复 Omicron 感染的可能性。

更新日期：2022-06-09

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11